Do Weight-Loss drugs save money? new study investigates

NCT ID NCT07640139

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow 125,000 adults with employer-based insurance to see how GLP-1 and GLP-1/GIP obesity medications (like Wegovy and Zepbound) affect weight, healthcare use, and medical costs. Researchers will compare people who take these drugs to those who don't, using existing medical and pharmacy claims data. The goal is to understand the real-world impact of these popular medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Incretin-based therapies (GLP-1 and GLP-1/GIP drugs like Wegovy, Zepbound)
What this could lead to: If successful, this study could provide real-world evidence on whether these medications improve health and reduce healthcare costs for people with obesity.
What could go wrong: This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to people outside employer-based insurance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Indiana University

Indianapolis, Indiana, 46203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.